Lipopen

Ezetimibe and Rosuvastatin, the active ingredients in Lipopen, are an ezetimibe and statin combination presented as a tablet for oral use. It treats hypercholesterolemia, mixed dyslipidemia and primary hyperlipidemia in adult patients. GNH USA supplies Lipopen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lipopen, a fixed‑dose combination of ezetimibe and rosuvastatin, is indicated for management of dyslipidemia and related lipid disorders. Hypercholesterolemia: lowers LDL‑cholesterol and total cholesterol to target levels. Mixed dyslipidemia: reduces triglycerides while modestly increasing HDL‑cholesterol. Primary hyperlipidemia: helps achieve recommended lipid goals to lower cardiovascular risk.

Adverse reactions may occur with Lipopen and should be monitored.

Common Side Effects: - Headache - Abdominal pain or discomfort - Myalgia or muscle aches - Diarrhea - Nausea - Elevated liver enzymes (ALT/AST)

Serious or Rare Side Effects: - Rhabdomyolysis or severe myopathy - Acute liver injury or hepatitis - Severe allergic reactions (rash, angioedema, anaphylaxis) - Elevated creatine kinase levels - Pancreatitis - Thrombocytopenia

Before initiating therapy, clinicians should consider several safety aspects. - Liver function monitoring: assess baseline transaminases and repeat periodically. - Renal impairment: adjust therapy in patients with severe renal dysfunction. - Drug interactions: review concomitant medications that affect CYP3A4 or statin metabolism. - Pregnancy and lactation: avoid use unless benefits outweigh potential risks. - Contraindications: do not use in active liver disease or unexplained persistent elevations of hepatic enzymes. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Lipopen may interact with several medicines; awareness of interaction severity guides management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole) – may increase rosuvastatin exposure. - Cyclosporine – markedly raises rosuvastatin plasma levels. - Gemfibrozil – raises risk of myopathy and rhabdomyolysis.

Moderate Interactions (Monitor Closely): - Bile‑acid sequestrants – may reduce ezetimibe absorption; separate dosing by at least 2 hours. - Other statins – additive risk of muscle toxicity; monitor CK. - Anticoagulants (warfarin) – potential alteration of INR; check coagulation status.